Prevalence and Risk Factors for Aspirin and Clopidogrel Resistance in Cerebrovascular Stenting

References

1. ↵
   Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113:e166–286

   FREE Full Text
2. ↵
   SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004;35:1388–92. Epub 2004 Apr 22

   Abstract/FREE Full Text
3. Fiorella D, Levy EI, Turk AS, et al. US multicenter experience with the Wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007;38:881–87. Epub 2007 Feb 8

   Abstract/FREE Full Text
4. ↵
   Henkes H, Miloslavski E, Lowens S, et al. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan). Neuroradiology 2005;47:222–28

   CrossRefPubMedWeb of Science
5. ↵
   Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 2005;115:101–08

   CrossRefPubMedWeb of Science
6. ↵
   Marcucci R, Paniccia R, Antonucci E, et al. Usefulness of aspirin resistance after percutaneous coronary intervention for acute myocardial infarction in predicting one-year major adverse coronary events. Am J Cardiol 2006;98:1156–59

   CrossRefPubMedWeb of Science
7. ↵
   Gurbel PA, Tantry US. Clopidogrel resistance? Thromb Res 2007;120:311–21

   CrossRefPubMedWeb of Science
8. ↵
   Lombard FW, Welsby IJ, Alexander MJ, et al. Thromboelastography detects inadequate response to abciximab therapy during stent-assisted cerebral aneurysm coil embolization complicated by stroke. Neurocrit Care 2006;4:32–34

   CrossRefPubMed
9. ↵
   Shenkman B, Schneiderman J, Tamarin I, et al. Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate(let) analyzer (CPA) methods. Thromb Res 2001;102:311–17

   CrossRefPubMedWeb of Science
10. ↵
    Chen WH, Lee PY, Ng W, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004;43:1122–26

    CrossRefPubMedWeb of Science
11. Gurbel PA, Lau WC, Bliden KP, et al. Clopidogrel resistance: implications for coronary stenting. Curr Pharm Des 2006;12:1261–69

    CrossRefPubMedWeb of Science
12. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171–75

    Abstract/FREE Full Text
13. ↵
    Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827–32

    CrossRefPubMedWeb of Science
14. ↵
    Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005;45:1392–96

    CrossRefPubMedWeb of Science
15. Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005;111:2560–64

    Abstract/FREE Full Text
16. ↵
    Kastrati A, von Beckerath N, Joost A, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004;110:1916–19

    Abstract/FREE Full Text
17. ↵
    Gurbel PA, Bliden KP, Zaman KA, et al. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153–59. Epub 2005 Feb 28

    Abstract/FREE Full Text
18. ↵
    Maree AO, Curtin RJ, Dooley M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005;46:1258–63

    CrossRefPubMedWeb of Science
19. Schwartz KA, Schwartz DE, Ghosheh K, et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005;95:973–75

    CrossRefPubMedWeb of Science
20. ↵
    Tantry US, Bliden KP, Gurbel PA. Resistance to antiplatelet drugs: current status and future research. Expert Opin Pharmacother 2005;6:2027–45

    CrossRefPubMedWeb of Science
21. ↵
    Macchi L, Christiaens L, Brabant S, et al. Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms. J Am Coll Cardiol 2003;42:1115–19

    CrossRefPubMedWeb of Science
22. ↵
    Undas A, Brummel K, Musial J, et al. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001;104:2666–72

    Abstract/FREE Full Text
23. ↵
    Nguyen T, Frishman WH, Nawarskas J, et al. Variability of response to clopidogrel: possible mechanisms and clinical implications. Cardiol Rev 2006;14:136–42

    CrossRefPubMed
24. ↵
    Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2007;120:188–92

    CrossRefPubMedWeb of Science
25. ↵
    Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004;109:166–71

    Abstract/FREE Full Text
26. ↵
    Taubert D, Kastrati A, Harlfinger S, et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004;92:311–16

    PubMedWeb of Science
27. ↵
    Soffer D, Moussa I, Harjai KJ, et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina? Catheter Cardiovasc Interv 2003;59:21–25

    CrossRefPubMedWeb of Science
28. ↵
    Neubauer H, Gunesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003;24:1744–49

    Abstract/FREE Full Text
29. ↵
    Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med 2004;164:2051–57

    CrossRefPubMedWeb of Science
30. ↵
    Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430–35

    Abstract/FREE Full Text
31. ↵
    Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): its relation to metabolic control. Thromb Res 2004;113:101–13

    CrossRefPubMedWeb of Science
32. ↵
    Winocour PD, Watala C, Perry DW, et al. Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins. Thromb Haemost 1992;68:577–82

    PubMedWeb of Science
33. ↵
    Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417–22

    Abstract/FREE Full Text
34. ↵
    Li Y, Woo V, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol 2001;280:H1480–89

    Abstract/FREE Full Text
35. ↵
    Tschoepe D, Roesen P, Esser J, et al. Large platelets circulate in an activated state in diabetes mellitus. Semin Thromb Hemost 1991;17:433–38

    CrossRefPubMedWeb of Science
36. ↵
    Angiolillo DJ, Shoemaker SB, Desai B, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708–16. Epub 2007 Jan 29

    Abstract/FREE Full Text
37. ↵
    Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:1820–26. Epub 2005 Oct 21

    CrossRefPubMedWeb of Science
38. ↵
    Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003;92:1492–94

    CrossRefPubMedWeb of Science
39. ↵
    Malinin A, Pokov A, Swaim L, et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006;28:315–22

    CrossRefPubMedWeb of Science